Editas Medicine Inc. (NASDAQ:EDIT) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday.
According to Zacks, “Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts. “
Shares of Editas Medicine (NASDAQ:EDIT) traded down 0.56% during midday trading on Tuesday, reaching $16.02. The company’s stock had a trading volume of 772,709 shares. Editas Medicine has a 12-month low of $12.57 and a 12-month high of $43.99. The firm’s market capitalization is $567.17 million. The stock has a 50-day moving average of $22.14 and a 200 day moving average of $29.14.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/06/editas-medicine-inc-edit-rating-increased-to-hold-at-zacks-investment-research-2/
Editas Medicine (NASDAQ:EDIT) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.54) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.54). Equities research analysts predict that Editas Medicine will post ($2.59) EPS for the current fiscal year.
Several large investors recently made changes to their positions in EDIT. Royal Bank of Canada bought a new stake in shares of Editas Medicine during the first quarter worth $164,000. Schonfeld Strategic Advisors LLC acquired a new position in Editas Medicine during the first quarter worth about $336,000. UBS Group AG acquired a new position in Editas Medicine during the first quarter worth about $452,000. Foresite Capital Management III LLC acquired a new position in Editas Medicine during the first quarter worth about $501,000. Finally, TIAA CREF Investment Management LLC acquired a new position in Editas Medicine during the first quarter worth about $518,000.
Several other equities analysts have also issued reports on EDIT. Cowen and Company reaffirmed a “buy” rating on shares of Editas Medicine in a report on Monday, May 16th. Vetr raised shares of Editas Medicine from a “hold” rating to a “buy” rating and set a $32.50 price objective on the stock in a report on Monday, May 9th. Finally, Jefferies Group reissued a “buy” rating on shares of Editas Medicine in a report on Monday, August 22nd. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Editas Medicine has an average rating of “Buy” and an average price target of $33.50.
Editas Medicine, Inc, formerly Gengine, Inc, is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology.
Receive News & Ratings for Editas Medicine Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Editas Medicine Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.